Adalimumab-induced pyoderma gangrenosum in a patient with hidradenitis suppurativa: A paradoxical reaction

Company-Quiroga, Jaime; Alique-García, Sergio; Martínez‐Morán, C.; Khedaoui, Radia; Romero‐Maté, Alberto; Borbujo, J.

doi:10.4103/ijdvl.ijdvl_277_18

Cited by 7 publications

(3 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…After abstract/title screening of 404 studies and full-text screening of 31 studies, 23 articles met the aforementioned inclusion criteria (Figure, Table, Supplemental Table 3, http://links.lww.com/NSW/A111). 9–31 This review presents a total of 57 patients between 24 and 82 years of age (mean, 51.3 years). Of the 57 patients, 10.5% were men (n = 6/57), 82.5% were women (n = 47/57), and the sex of 7.0% of patients was not reported (n = 4/57).…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Onset of Pyoderma Gangrenosum in Patients on Biologic Therapies: A Systematic Review

Mufti

Maliyar

Sachdeva

et al. 2022

Adv Skin Wound Care

View full text Add to dashboard Cite

OBJECTIVE:To summarize clinical outcomes of paradoxical pyoderma gangrenosum (PG) onset in patients on biologic therapy. METHODS:The authors conducted MEDLINE and EMBASE searches using PRISMA guidelines to include 57 patients (23 reports). RESULTS:Of the included patients, 71.9% (n = 41/57) noted PG onset after initiating rituximab, 21.1% (n = 12/57) noted tumor necrosis factor α (TNF-α) inhibitors, 5.3% (n = 3/57) reported interleukin 17A inhibitors, and 1.8% (n = 1/57) reported cytotoxic T-lymphocyte-associated protein 4 antibodies. The majority of patients (94.3%) discontinued biologic use. The most common medications used to resolve rituximab-associated PG were intravenous immunoglobulins, oral corticosteroids, and antibiotics, with an average resolution time of 3.3 months. Complete resolution of PG in TNF-α-associated cases occurred within an average of 2.2 months after switching to another TNF-α inhibitor (n = 1), an interleukin 12/23 inhibitor (n = 2), or treatment with systemic corticosteroids and cyclosporine (n = 3), systemic corticosteroids alone (n = 1), or cyclosporine alone (n = 1). CONCLUSIONS:Further investigations are warranted to determine whether PG onset is associated with underlying comorbidities, the use of biologic agents, or a synergistic effect. Nevertheless, PG may develop in patients on rituximab or TNF-α inhibitors, suggesting the need to monitor and treat such adverse effects.

show abstract

Section: Resultsmentioning

confidence: 99%

“…Anti-CD20 (n = 41) [9][10][11][12][13][14][15] TNF-α Inhibitor (n = 12) [16][17][18][19][20][21][22][23][24][25][26][27] IL-17A Inhibitor (n = 3) [28][29][30] CTLA-4 Antibody (n = 1) 31 Biologic name (n) Rituximab ( 41) Infliximab ( 5) Adalimumab ( 4) Certolizumab ( 1) Etanercept ( 1)…”

Section: Table Summary Of Pg Reactions During Treatment With Differen...mentioning

confidence: 99%

Onset of Pyoderma Gangrenosum in Patients on Biologic Therapies: A Systematic Review

Mufti

Maliyar

Sachdeva

et al. 2022

Adv Skin Wound Care

View full text Add to dashboard Cite

show abstract

“…Hierzu zählen neben der paradoxen Psoriasis (häufig mit palmoplantarer Beteiligung) auch das Sweet-Syndrom, Pyoderma gangraenosum etc. [11,12]. Bei all diesen paradoxen Reaktionen ist eine neutrophile Infiltration charakteristisch.…”

Section: Introductionunclassified

Erythema elevatum et diutinum – eine mögliche IgA-vermittelte Reaktion nach einer Behandlung mit Adalimumab

Al-Gburi

Appelt

Beissert

et al. 2021

Aktuelle Dermatologie

View full text Add to dashboard Cite

ZusammenfassungDas Erythema elevatum et diutinum ist eine eigenständige Form der leukozytoklastischen Vaskulitis, die mit systemischen Krankheiten assoziiert sein kann. Hier präsentieren wir Ihnen einen Patienten, der nach jahrelanger Therapie mit Adalimumab schmerzhafte Knoten an den Füßen und Knien entwickelte. Begleitend zeigte sich eine prominente (polyklonale) IgA-Hypergammaglobulinämie ohne Anhalt für eine hämatoonkologische Grunderkrankung. Dapson erwies sich als eine effektive Therapieoption.

show abstract

Adalimumab

2019

Reactions Weekly

View full text Add to dashboard Cite

Adalimumab-induced pyoderma gangrenosum in a patient with hidradenitis suppurativa: A paradoxical reaction

Cited by 7 publications

References 0 publications

Onset of Pyoderma Gangrenosum in Patients on Biologic Therapies: A Systematic Review

Onset of Pyoderma Gangrenosum in Patients on Biologic Therapies: A Systematic Review

Erythema elevatum et diutinum – eine mögliche IgA-vermittelte Reaktion nach einer Behandlung mit Adalimumab

Adalimumab

Contact Info

Product

Resources

About